Generics vs. Biosimilars: Why They're Not the Same Business
Generics and biosimilars have the same goal: cheaper versions of drugs whose patents have expired. That is where the similarity ends.
A generic is a commodity. It copies a small-molecule drug made by simple chemistry, and the copy is identical to the original. Because anyone can make it, many companies enter, prices collapse, and the winners are whoever can make it cheapest and most reliably.
A biosimilar is a product you have to build. It copies a large, complex drug grown in living cells. It can't be an exact copy, so the maker must prove it works the same way, then build its own manufacturing process from scratch. That takes years and a lot of capital, which keeps the number of competitors small.
Those differences carry through everything in this post: development time and cost, how fast prices fall, and what margins companies can earn. A third factor matters just as much. A pharmacist can swap a generic at the counter, but biosimilar sales depend largely on whether doctors, insurers and pharmacy benefit managers decide to favor them. The result is that biosimilars are a more attractive business than generics, but the opportunity is uneven.
Key terms
- Biologic: a large, complex drug made in living cells, such as Humira or Keytruda.
- Biosimilar: a highly similar, but not identical, copy of an approved biologic with no clinically meaningful differences. The original is called the reference product.
- Interchangeable: a US designation that lets a pharmacist substitute a biosimilar without a new prescription.
- Loss of exclusivity (LOE): when patents and regulatory protections end and competition can legally begin.
- ANDA / 351(k) BLA: the US approval pathways for generics and biosimilars, respectively. The BPCIA is the 2010 law that created the biosimilar pathway.
- PBM (pharmacy benefit manager): an intermediary that negotiates drug prices and sets coverage for insurers and employers. The three largest are affiliated with the companies behind the main private-label biosimilars.
- Formulary: the list of drugs a plan covers, and at what patient cost.
- Rebate: a confidential payment from a drug maker to a PBM or payer in exchange for favorable coverage.
- List price (WAC) vs. net price: the list price is the sticker price. It excludes rebates, hospital discounts, 340B reductions and other adjustments, so net price, what payers actually pay, is lower and confidential.
- Private label: a biosimilar sold through a PBM-affiliated company, such as Cordavis or Quallent.
- Pharmacy benefit vs. medical benefit: under the pharmacy benefit, drugs are dispensed by a pharmacy (often self-injected) and the PBM controls coverage. Under the medical benefit, a clinician administers the drug (an infusion or in-clinic injection), the provider buys it, and the insurer reimburses it, usually based on average sales price (ASP).
- CDMO: a contract manufacturer that makes drugs for other companies.
- CRL (complete response letter): an FDA letter declining to approve an application until issues are fixed.
We are up 20% this year.
Biocompounding’s portfolio is now accessible to all readers.
